AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03284099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEi, ARB
Description: To take the ACEis or ARBs before bedtime instead of in the morning
Study NCT03284099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEi, ARB
Description: To take the ACEis or ARBs before bedtime instead of in the morning
Study NCT04134390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation
Study NCT02807675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301, LIP
Description: All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
Study NCT02807675 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
Study NCT04181814 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound
Description: Use ultrasound to assess gastric contents in diabetic patients before anesthesia
Study NCT01292902 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: inspiratory muscle exercise
Description: To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 \< 88%.
Study NCT01292902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory muscle exercise
Description: Equal to the group with chronic heart failure.
Study NCT01691651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous injection of botulinum toxin type A
Description: Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
Study NCT01691651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: 2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
Study NCT01626716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care management
Description: patients who assigned to the intervention group will take 7 times phone calls from case manager
Study NCT02308878 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health cognitive stimulation
Study NCT04320667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry analysis of urine samples
Description: Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326
Study NCT03772873 — intervention group
Intervention type: PROCEDURE
Intervention: minimally invasive pilonidal excision
Description: MIPE procedure with trephine excision of pits and sinuses
Study NCT00121875 — intervention group
Intervention type: DRUG
Intervention: somatropin (rDNA)
Description: Form/Strength: 10 mg aqueous suspension; 5 mg/ml~Dosage/Frequency: 0.35 mg/kg/week, daily divided doses~Duration: 6 months with 3-month washout period
Study NCT04053738 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-snoring bed
Description: The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
Study NCT01568814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low volume PEG
Description: low volume polyethylene glycol 2 liter one time
Study NCT01568814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: high volume PEG
Description: high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
Study NCT02280278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Study NCT02280278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery
Study NCT02280278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Study NCT02280278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Study NCT02280278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cell immunotherapy
Study NCT01332071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg
Description: Avandamet reference product
Study NCT01332071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg
Description: Avandamet test product
Study NCT01445678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-201 and metronidazole
Description: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
Study NCT01445678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem IV infusion (1000mg q8h) for 4-14 days
Study NCT03644238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral Glucose Tolerance Test
Description: 75g of glucose is consumed
Study NCT03644238 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: 75g of glucose is consumed
Study NCT03644238 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inactivity
Description: Lying or sitting down.
Study NCT03644238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 20 minutes of fixed intensity exercise on a bicycle ergometer.
Study NCT04152096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rheosorbilact®
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.
Study NCT04152096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Study NCT01393197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization
Study NCT01393197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization
Study NCT04509622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral
Study NCT02233413 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active LLLT helmet application
Description: LED helmet applied with light activated
Study NCT04509622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Subcutaneous Injection
Study NCT01534897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: 150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
Study NCT01509053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole (Abilify®) IM Depot Injection
Description: 400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.~Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014.
Study NCT01509053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral aripiprazole
Description: Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
Study NCT00388193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RITUXIMAB
Description: 375 mg/m2/d day 1
Study NCT03279640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS on ipsilesional M1
Study NCT03279640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS on contralesional M1
Study NCT02906605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-809
Description: JNJ-809 (1\*10\^9) colony forming units (CFU) given as an infusion.
Study NCT02906605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg orally daily.
Study NCT02233413 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-active LLLT helmet application
Description: LED helmet applied without light activated
Study NCT00587457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 5 mcg/kg
Description: Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Study NCT00587457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 10 mcg/kg
Description: Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Study NCT00587457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-8015 20 mcg/kg
Description: Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
Study NCT01259999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calogen extra strawberry
Description: A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
Study NCT00008697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study NCT00620529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocean Nutrition 2050
Description: 1000mg capsules, 4 capsules/day for 8 weeks
Study NCT00620529 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil capsules
Description: Olive oil capsules, 4 per day for 8 weeks
Study NCT02842190 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: after ekstubation
Study NCT04138017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ViviGen
Description: A cellular bone matrix which includes viable osteoblasts within a corticocancellous and demineralized bone carrier, represents a unique alternative to autograft or existing products which utilize mesenchymal stem cells.
Study NCT00895713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular hepatitis B virus immune globulin
Description: Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
Study NCT01644929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
Study NCT01616693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: A capsule that contains at least 1 x 10\^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.
Study NCT01616693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: A capsule that contains at least 1 x 10\^9 Lactobacillus rhamnosus GG organisms per capsule. The contents of this capsule were given once daily orally.
Study NCT01616693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc
Description: Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.
Study NCT01616693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc sulphate syrup is zinc sulphate heptahydrate (concentration 1mg/ml). 5 ml of this suspension was given once daily orally.
Study NCT01616693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic placebo
Description: The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.
Study NCT01616693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic placebo
Description: The probiotic placebo was manufactured by the same company that manufactured the probiotic and contained inulin powder but no Lactobacillus rhamnosus GG. The contents of the capsule were given once daily orally.
Study NCT01616693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc placebo
Description: The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.
Study NCT01616693 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc placebo
Description: The zinc placebo excluded the zinc sulphate but contained lactose and was diluted to match the taste. 5 ml of this suspension was given orally once daily.
Study NCT01616693 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rotavirus vaccine
Description: 1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
Study NCT01616693 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine
Description: 1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
Study NCT01616693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: 1 ml Rotarix®, a lyophilized human rotavirus vaccine reconstituted with calcium carbonate buffer provided orally at 6 and 10 weeks.
Study NCT01616693 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral polio vaccine
Description: A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
Study NCT01644929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham stimulation, then tDCS
Description: Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks
Study NCT01644929 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham stimulation for 30 seconds on 15 days during 6 weeks
Study NCT01616693 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral polio vaccine
Description: A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
Study NCT01616693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral polio vaccine
Description: A liquid trivalent polio vaccine provided orally at 6 and 10 weeks.
Study NCT03739021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Single shot of the Bupivacaine Liposome, and then we follow up with patient in the recovery room with traditional common pain management. MME (milligram morphine equivalent) will be collected.
Study NCT03881787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EGFR monoclonal antibody
Description: Recombinant anti-EGFR human mouse chimeric monoclonal antibody injection
Study NCT03881787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab injection
Description: Cetuximab injection
Study NCT03653741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 6 MG
Description: Perampanel is a drug approved and marketed in the USA for the treatment of epilepsy to prevent recurrent seizures. In a previous study, healthy volunteers have tolerated a single dose of perampanel at 6 mg quite well.
Study NCT03219580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
Study NCT03219580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: 0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
Study NCT00564980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wafer Procedure
Description: A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
Study NCT00564980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ulnar shortening osteotomy
Description: A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
Study NCT00964704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv every 3 weeks
Study NCT00964704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
Study NCT00964704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
Study NCT00964704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
Study NCT03118882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet group
Description: A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.
Study NCT03118882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity group
Description: A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.
Study NCT03118882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity and diet group
Description: A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
Study NCT03628326 — intervention group
Intervention type: OTHER
Intervention: Pulmonary arterial tree
Description: The investigators performed 3D reconstruction of the pulmonary arterial tree on the CT angiography data set acquired during preoperative work-up.
Study NCT04377867 — intervention group
Intervention type: DRUG
Intervention: Abatacept Injection [Orencia]
Description: Patients on abatacept to control disease symptoms